Anita Abhyankar1, Alan C Moss. 1. Center for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Abstract
BACKGROUND: A number of controlled trials and prospective studies have compared intravenous (IV) to oral (PO) iron for the treatment of iron deficiency anemia with mixed results. METHODS: We conducted a systematic review of trials published on 2014 that compared IV with PO iron to treat in patients with IBD. Meta-analysis was performed to generate effect estimates. Quality assessment was also performed according to GRADE criteria. RESULTS: Five studies met our inclusion criteria, enrolling 694 patients. For the primary outcome of "response" (hemoglobin rise >2 g/dL), there was no significant difference between IV or PO iron; risk ratio for response with IV was 1.08 (95% CI, 0.9-1.2; P = 0.2). For the secondary outcome of mean change in hemoglobin (g/dL), the mean difference between PO and IV iron was not statistically significant (mean difference, 0.6 g/dL, 96% CI, -0.1 to 1.3; P = 0.08). IV iron was associated with a significantly greater initial rise in serum ferritin compared with PO iron (mean difference 89 ng/mL; 95% CI, 29-148, P = 0.003). There was a lower risk of withdrawal due to adverse events in these trials in the IV iron cohorts when compared with PO iron (risk ratio, 0.4; 95% CI, 0.1-1.0; P = 0.05). CONCLUSIONS: We found no significant difference between IV and PO iron in correcting iron-deficiency anemia in patients with IBD in this meta-analysis. Patients who received IV iron had a greater rise in serum ferritin and were less likely to stop treatment due to adverse events, when compared with those who received PO iron.
BACKGROUND: A number of controlled trials and prospective studies have compared intravenous (IV) to oral (PO) iron for the treatment of iron deficiency anemia with mixed results. METHODS: We conducted a systematic review of trials published on 2014 that compared IV with PO iron to treat in patients with IBD. Meta-analysis was performed to generate effect estimates. Quality assessment was also performed according to GRADE criteria. RESULTS: Five studies met our inclusion criteria, enrolling 694 patients. For the primary outcome of "response" (hemoglobin rise >2 g/dL), there was no significant difference between IV or PO iron; risk ratio for response with IV was 1.08 (95% CI, 0.9-1.2; P = 0.2). For the secondary outcome of mean change in hemoglobin (g/dL), the mean difference between PO and IV iron was not statistically significant (mean difference, 0.6 g/dL, 96% CI, -0.1 to 1.3; P = 0.08). IV iron was associated with a significantly greater initial rise in serum ferritin compared with PO iron (mean difference 89 ng/mL; 95% CI, 29-148, P = 0.003). There was a lower risk of withdrawal due to adverse events in these trials in the IV iron cohorts when compared with PO iron (risk ratio, 0.4; 95% CI, 0.1-1.0; P = 0.05). CONCLUSIONS: We found no significant difference between IV and PO iron in correcting iron-deficiency anemia in patients with IBD in this meta-analysis. Patients who received IV iron had a greater rise in serum ferritin and were less likely to stop treatment due to adverse events, when compared with those who received PO iron.
Authors: Oliver Schröder; Oliver Mickisch; Ursula Seidler; Andreas de Weerth; Axel U Dignass; Hans Herfarth; Max Reinshagen; Stefan Schreiber; Ulrich Junge; Marc Schrott; Jürgen Stein Journal: Am J Gastroenterol Date: 2005-11 Impact factor: 10.864
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: Christoph Gasche; Arnold Berstad; Ragnar Befrits; Christoph Beglinger; Axel Dignass; Kari Erichsen; Fernando Gomollon; Henrik Hjortswang; Ioannis Koutroubakis; Stefanie Kulnigg; Bas Oldenburg; David Rampton; Oliver Schroeder; Jürgen Stein; Simon Travis; Gert Van Assche Journal: Inflamm Bowel Dis Date: 2007-12 Impact factor: 5.325
Authors: Melissa Ellermann; Raad Z Gharaibeh; Nitsan Maharshak; Ernesto Peréz-Chanona; Christian Jobin; Ian M Carroll; Janelle C Arthur; Scott E Plevy; Anthony A Fodor; Cory R Brouwer; R Balfour Sartor Journal: Gut Microbes Date: 2019-06-10